Edward Schutter Net Worth

The estimated Net Worth of Edward J Schutter is at least $12.2 Million dollars as of 23 November 2021. Mr. Schutter owns over 32,467 units of Establishment Labs Inc stock worth over $12,238,056 and over the last 6 years he sold ESTA stock worth over $0. In addition, he makes $0 as Independent Director at Establishment Labs Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Schutter ESTA stock SEC Form 4 insiders trading

Edward has made over 2 trades of the Establishment Labs Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 32,467 units of ESTA stock worth $2,164,250 on 23 November 2021.

The largest trade he's ever made was buying 32,560 units of Establishment Labs Inc stock on 17 November 2021 worth over $2,336,506. On average, Edward trades about 4,064 units every 0 days since 2018. As of 23 November 2021 he still owns at least 298,562 units of Establishment Labs Inc stock.

You can see the complete history of Mr. Schutter stock trades at the bottom of the page.

Edward Schutter biography

Edward James Schutter serves as Independent Director of the Company. He has over thirty years of pharmaceutical industry experience and has served as the Chief Executive Officer of Arbor Pharmaceuticals, Inc. since April 2010. Prior to joining Arbor Pharmaceuticals Inc., Mr. Schutter served in various roles at Sciele Pharma, Inc., a subsidiary of Shionogi & Co., Ltd., including as President and Chief Operating Officer from 2007 to 2009. Prior to Shionogi he was Vice President of Global Business Development at Solvay Pharmaceuticals based in Basel, Switzerland. He also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. Mr. Schutter began his pharmaceutical career with Reid-Provident Laboratories, Inc., a pharmaceutical company that was based in Atlanta, Georgia which was later acquired by Solvay. He also serves on the board of Vitruvias Therapeutics Inc. and has previously served on the boards of Mercer University, Vensun Pharmaceuticals, Knight Therapeutics (GUD.TO), Georgia Bio, Emory University new venture advisory board and several charitable organizations. Mr. Schutter has a bachelor’s degree in Pharmaceutical Sciences from Mercer University and an M.B.A. from Kennesaw State University.

How old is Edward Schutter?

Edward Schutter is 68, he's been the Independent Director of Establishment Labs Inc since 2015. There are 1 older and 16 younger executives at Establishment Labs Inc. The oldest executive at Establishment Labs Holdings Inc is Dennis Condon, 83, who is the Independent Director.

What's Edward Schutter's mailing address?

Edward's mailing address filed with the SEC is C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES, DE, 19958.

Insiders trading at Establishment Labs Inc

Over the last 6 years, insiders at Establishment Labs Inc have traded over $8,492,826 worth of Establishment Labs Inc stock and bought 169,894 units worth $9,905,657 . The most active insiders traders include David Hung, Nicholas Sheridan Lewin, and Quiros Juan Jose Chacon. On average, Establishment Labs Inc executives and independent directors trade stock every 34 days with the average trade being worth of $513,072. The most recent stock trade was executed by Quiros Juan Jose Chacon on 11 July 2024, trading 3,641 units of ESTA stock currently worth $163,991.

What does Establishment Labs Inc do?

establishment labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. with more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for establishment labs’ founders and top executives. as a result, motiva implants® has established a level of product innovation that always results in safety. and while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. we believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.

Complete history of Mr. Schutter stock trades at Establishment Labs Inc

Establishment Labs Inc executives and stock owners

Establishment Labs Inc executives and other stock owners filed with the SEC include:

• Juan Jose Chacon Quiros,
  Founder, CEO & Exec. Director
• Juan Jose Chacon Quiros,
  Chief Executive Officer, Director
• Salvador Santos Dada,
  Chief Operating Officer (Medical Leave of Absence)
• Renee Gaeta,
  Chief Financial Officer
• Salvador Santos,
  Chief Operating Officer
• Eddie De Oliveira,
  Vice President of Sales Latin America
• David Erickson,
  IR Contact Officer
• Edward Schutter,
  Independent Director
• David Hung,
  Independent Director
• Lisa Gersh,
  Independent Director
• Dennis Condon,
  Independent Director
• Lisa Colleran,
  Independent Director
• Jeremy Livianu,
  General Counsel
• Alberto Quesada,
  Vice President - Quality & OUS Regulatory Affairs
• Roberto De Mezerville,
  Chief Technology Officer
• Nicholas Lewin,
  Chairman of the Board
• Roberto de Mezerville,
  Chief Technology Officer
• Rosalyn Cole d'Incelli,
  VP of Clinical & Medical Affairs
• Eddie De Oliveira,
  VP of Sales, Brazil
• Dr. Heather Brennan,
  Head of U.S. Commercial Operations
• Jeffrey Clark Bettinger,
  Global Head of People
• Neeta Toprani,
  Gen. Counsel & Corp. Sec.
• Roberto De Mezerville,
  Chief Technology Officer
• Pratip Dastidar,
  Head of Global Operations
• Rajbir Singh Denhoy,
  CFO and Head of Strategy & Investor Relations
• Paul D. Rodio,
  Chief Operating Officer
• Tu, Lp Cph,
  10% owner
• Asset Management, Llcjw Par...,
  
• Pratip Dastidar,
  Head of Global Operations
• Ann Custin,
  Director
• Bryan Slotkin,
  Director
• Leslie Gillin,
  Director
• Raj Denhoy,
  Chief Financial Officer
• Samuel Ross Mansbach,
  
• Filippo Caldini,
  President